Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Chronic exposure to stress hormones promotes transformation and tumorigenicity of 3T3 mouse fibroblasts.

Flint MS, Baum A, Episcopo B, Knickelbein KZ, Liegey Dougall AJ, Chambers WH, Jenkins FJ.

Stress. 2013 Jan;16(1):114-21. doi: 10.3109/10253890.2012.686075. Epub 2012 May 16.

2.

Prevention of mammary carcinogenesis in MMTV-neu mice by cruciferous vegetable constituent benzyl isothiocyanate.

Warin R, Chambers WH, Potter DM, Singh SV.

Cancer Res. 2009 Dec 15;69(24):9473-80. doi: 10.1158/0008-5472.CAN-09-2960.

3.

Magnetic resonance imaging-guided adoptive cellular immunotherapy of central nervous system tumors with a T1 contrast agent.

Sengar RS, Spokauskiene L, Steed DP, Griffin P, Arbujas N, Chambers WH, Wiener EC.

Magn Reson Med. 2009 Sep;62(3):599-606. doi: 10.1002/mrm.22030.

4.

Sulforaphane inhibits prostate carcinogenesis and pulmonary metastasis in TRAMP mice in association with increased cytotoxicity of natural killer cells.

Singh SV, Warin R, Xiao D, Powolny AA, Stan SD, Arlotti JA, Zeng Y, Hahm ER, Marynowski SW, Bommareddy A, Desai D, Amin S, Parise RA, Beumer JH, Chambers WH.

Cancer Res. 2009 Mar 1;69(5):2117-25. doi: 10.1158/0008-5472.CAN-08-3502. Epub 2009 Feb 17.

5.

Induction of DNA damage, alteration of DNA repair and transcriptional activation by stress hormones.

Flint MS, Baum A, Chambers WH, Jenkins FJ.

Psychoneuroendocrinology. 2007 Jun;32(5):470-9. Epub 2007 Apr 24.

PMID:
17459596
6.
7.

Genomic profiling of restraint stress-induced alterations in mouse T lymphocytes.

Flint MS, Carroll JE, Jenkins FJ, Chambers WH, Han ML, Baum A.

J Neuroimmunol. 2005 Oct;167(1-2):34-44.

PMID:
16026860
8.

The characterization of tumor apoptosis after experimental radiosurgery.

Witham TF, Okada H, Fellows W, Hamilton RL, Flickinger JC, Chambers WH, Pollack IF, Watkins SC, Kondziolka D.

Stereotact Funct Neurosurg. 2005;83(1):17-24. Epub 2005 Mar 15.

PMID:
15775705
9.

A novel epitope of N-CAM defines precursors of human adherent NK cells.

Li S, Xu J, Makarenkova VP, Tjandrawan T, Vakkila J, Reichert T, Gooding W, Lagenaur CF, Achim CL, Chambers WH, Herberman RB, Whiteside TL, Vujanovic NL.

J Leukoc Biol. 2004 Dec;76(6):1187-99. Epub 2004 Sep 8.

PMID:
15356097
10.

Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines.

Okada H, Tsugawa T, Sato H, Kuwashima N, Gambotto A, Okada K, Dusak JE, Fellows-Mayle WK, Papworth GD, Watkins SC, Chambers WH, Potter DM, Storkus WJ, Pollack IF.

Cancer Res. 2004 Aug 15;64(16):5830-8.

11.

Expression of a soluble transforming growth factor-beta (TGFbeta) receptor reduces tumorigenicity by regulating natural killer (NK) cell activity against 9L gliosarcoma in vivo.

Witham TF, Villa L, Yang T, Pollack IF, Okada H, Robbins PD, Chambers WH.

J Neurooncol. 2003 Aug-Sep;64(1-2):63-9.

PMID:
12952287
12.

Stability of individual differences in cellular immune responses to two different laboratory tasks.

Marsland AL, Henderson BN, Chambers WH, Baum A.

Psychophysiology. 2002 Nov;39(6):865-8.

PMID:
12462514
13.

Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain.

Okano F, Storkus WJ, Chambers WH, Pollack IF, Okada H.

Clin Cancer Res. 2002 Sep;8(9):2851-5. Erratum in: Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3552.

14.

Flt-3 ligand (FL) drives differentiation of rat bone marrow-derived dendritic cells expressing OX62 and/or CD161 (NKR-P1).

Brissette-Storkus CS, Kettel JC, Whitham TF, Giezeman-Smits KM, Villa LA, Potter DM, Chambers WH.

J Leukoc Biol. 2002 Jun;71(6):941-9.

PMID:
12050178
15.
16.

Glioma-associated hyaluronan induces apoptosis in dendritic cells via inducible nitric oxide synthase: implications for the use of dendritic cells for therapy of gliomas.

Yang T, Witham TF, Villa L, Erff M, Attanucci J, Watkins S, Kondziolka D, Okada H, Pollack IF, Chambers WH.

Cancer Res. 2002 May 1;62(9):2583-91.

17.

Combination of stereotactic radiosurgery and cytokine gene-transduced tumor cell vaccination: a new strategy against metastatic brain tumors.

Nakahara N, Okada H, Witham TF, Attanucci J, Fellows WK, Chambers WH, Niranjan A, Kondziolka D, Pollack IF.

J Neurosurg. 2001 Dec;95(6):984-9.

PMID:
11765844
18.

Cytokine gene therapy of gliomas: effective induction of therapeutic immunity to intracranial tumors by peripheral immunization with interleukin-4 transduced glioma cells.

Okada H, Villa L, Attanucci J, Erff M, Fellows WK, Lotze MT, Pollack IF, Chambers WH.

Gene Ther. 2001 Aug;8(15):1157-66.

19.

Immunization with an antigen identified by cytokine tumor vaccine-assisted SEREX (CAS) suppressed growth of the rat 9L glioma in vivo.

Okada H, Attanucci J, Giezeman-Smits KM, Brissette-Storkus C, Fellows WK, Gambotto A, Pollack LF, Pogue-Geile K, Lotze MT, Bozik ME, Chambers WH.

Cancer Res. 2001 Mar 15;61(6):2625-31.

20.

Exploitation of immune mechanisms in the treatment of central nervous system cancer.

Pollack IF, Okada H, Chambers WH.

Semin Pediatr Neurol. 2000 Jun;7(2):131-43. Review.

PMID:
10914414
21.

Methods for in vivo analyses of natural killer (NK) cells.

Chambers WH, Watkins SM, Basse PH.

Methods Mol Biol. 2000;121:95-114. Review. No abstract available.

PMID:
10818720
22.

Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.

Giezeman-Smits KM, Okada H, Brissette-Storkus CS, Villa LA, Attanucci J, Lotze MT, Pollack IF, Bozik ME, Chambers WH.

Cancer Res. 2000 May 1;60(9):2449-57.

23.

Characterization and transduction of a retroviral vector encoding human interleukin-4 and herpes simplex virus-thymidine kinase for glioma tumor vaccine therapy.

Okada H, Attanucci J, Tahara H, Pollack IF, Bozik ME, Chambers WH, Lotze MT.

Cancer Gene Ther. 2000 Mar;7(3):486-94.

24.

Acute stress impairs NK cell adhesion and cytotoxicity through CD2, but not LFA-1.

Rogers CJ, Brissette-Storkus CS, Chambers WH, Cameron JL.

J Neuroimmunol. 1999 Oct 29;99(2):230-41.

PMID:
10505980
25.

Ligand binding specificities and signal transduction pathways of Fc gamma receptor IIc isoforms: the CD32 isoforms expressed by human NK cells.

Metes D, Manciulea M, Pretrusca D, Rabinowich H, Ernst LK, Popescu I, Calugaru A, Sulica A, Chambers WH, Herberman RB, Morel PA.

Eur J Immunol. 1999 Sep;29(9):2842-52.

26.
27.

Effective cytokine gene therapy against an intracranial glioma using a retrovirally transduced IL-4 plus HSVtk tumor vaccine.

Okada H, Giezeman-Smits KM, Tahara H, Attanucci J, Fellows WK, Lotze MT, Chambers WH, Bozik ME.

Gene Ther. 1999 Feb;6(2):219-26.

28.

The development of a bi-specific anti-CD161A x anti-tumor antibody for rat NK cell targeting.

Hagenaars M, Ensink NG, Jonges LE, Chambers WH, Eggermont AM, van de Velde CJ, Fleuren GJ, Kuppen PJ.

Immunobiology. 1999 Feb;200(1):31-48.

PMID:
10084694
29.

Evidence for involvement of B lymphocytes in the surveillance of lung metastasis in the rat.

Quan N, Zhang Z, Demetrikopoulos MK, Kitson RP, Chambers WH, Goldfarb RH, Weiss JM.

Cancer Res. 1999 Mar 1;59(5):1080-9.

30.

Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms.

Okada H, Tahara H, Shurin MR, Attanucci J, Giezeman-Smits KM, Fellows WK, Lotze MT, Chambers WH, Bozik ME.

Int J Cancer. 1998 Oct 5;78(2):196-201.

31.

Selective reduction in CD2 expression on CD2bright/CD8+ lymphocytes from cynomolgus monkeys (Macaca fascicularis) in response to acute stress.

Rogers CJ, Brissette-Storkus CS, Hayes LA, Cameron JL, Chambers WH.

J Neuroimmunol. 1998 Jun 1;86(1):63-73.

PMID:
9655473
32.

Expression of functional CD32 molecules on human NK cells is determined by an allelic polymorphism of the FcgammaRIIC gene.

Metes D, Ernst LK, Chambers WH, Sulica A, Herberman RB, Morel PA.

Blood. 1998 Apr 1;91(7):2369-80.

PMID:
9516136
33.

Importance of natural killer cells in the rejection of hamster skin xenografts.

Gourlay WA, Chambers WH, Monaco AP, Maki T.

Transplantation. 1998 Mar 15;65(5):727-34.

PMID:
9521210
34.

Novel monoclonal antibodies against membrane structures that are preferentially expressed on IL-2-activated rat NK cells.

Giezeman-Smits KM, Jonges LE, Chambers WH, Brisette-Storkus CS, Van Vlierberghe RL, Van Eendenburg JD, Eggermont AM, Fleuren GJ, Kuppen PJ.

J Leukoc Biol. 1998 Feb;63(2):209-15.

PMID:
9468279
35.

Impact of RT1.C-encoded MHC antigens on host-versus-graft and graft versus-host reactions in a model of small bowel transplantation in the rat.

Fändrich F, Zhu X, Dresske B, Papachrysanthou A, Exner B, Chambers WH.

Transplant Proc. 1997 May;29(3):1730-1. No abstract available.

PMID:
9142251
36.

The role of adrenocorticoids as modulators of immune function in health and disease: neural, endocrine and immune interactions.

McEwen BS, Biron CA, Brunson KW, Bulloch K, Chambers WH, Dhabhar FS, Goldfarb RH, Kitson RP, Miller AH, Spencer RL, Weiss JM.

Brain Res Brain Res Rev. 1997 Feb;23(1-2):79-133. Review. No abstract available.

PMID:
9063588
37.

Suppression of splenic T lymphocyte proliferation by acute cocaine administration.

Piccotti JR, Brissette-Storkus CS, Chambers WH, Bricker JD.

Life Sci. 1997;61(10):967-76.

PMID:
9296335
38.

Modulation of graft-vs-host-related disease by host-specific natural killer cell activity following semiallogeneic small bowel transplantation in the rat.

Fändrich F, Schröder J, Jahnke T, Dresske B, Chambers WH, Zavazava N.

Transplant Proc. 1996 Dec;28(6):3267-8. No abstract available.

PMID:
8962268
39.

Impact of natural killer cells in mediating graft-versus-host disease following small bowel transplantation in a rat model.

Fändrich F, Exner B, Papachrysanthou A, Jahnke T, Chambers WH, Zavazava N.

Transplant Proc. 1996 Oct;28(5):2465-6. No abstract available.

PMID:
8907904
40.

NKR-P1+ cells localize selectively in Rat 9L gliosarcomas but have reduced cytolytic function.

Chambers WH, Bozik ME, Brissette-Storkus SC, Basse P, Redgate E, Watkins S, Boggs SS.

Cancer Res. 1996 Aug 1;56(15):3516-25.

41.
42.

NKR-P1dim/TCR alpha beta + T cells and natural killer cells share expression of NKR-P1A and NKR-P1D.

Appasamy PM, Kenniston TW, Brissette-Storkus CS, Chambers WH.

Nat Immun. 1996-1997;15(5):259-68.

PMID:
9390275
43.

In vivo depletion of NKR-P1 positive cells in the recipient prior to small bowel transplantation enhances graft-versus-host disease (GvHD) in the rat.

Fändrich F, Exner B, Papachrysanthou A, Zhu X, Jahnke T, Chambers WH, Zavazava N.

Transpl Int. 1996;9 Suppl 1:S275-80.

PMID:
8959845
44.

High expression of NKR-P1 is not an absolute requirement for natural killer activity in BDIX rats.

Pinard D, Olsson NO, Chambers WH, Martin F.

Cancer Immunol Immunother. 1996 Jan;42(1):15-23.

PMID:
8625362
45.

Hanging in the balance: natural killer cell recognition of target cells.

Chambers WH, Brissette-Storkus CS.

Chem Biol. 1995 Jul;2(7):429-35. Review.

46.

Changes of liver-resident NK cells during liver regeneration in rats.

Vujanovic NL, Polimeno L, Azzarone A, Francavilla A, Chambers WH, Starzl TE, Herberman RB, Whiteside TL.

J Immunol. 1995 Jun 15;154(12):6324-38.

PMID:
7759871
47.

Paradoxical rejection pattern of donor small bowel in young F1-rats in a graft-versus-host strain combination.

Fändrich F, Exner B, Papachrysanthou A, Chambers WH, Zavazava N.

Transplant Proc. 1995 Apr;27(2):1620-1. No abstract available.

PMID:
7725426
48.

Prolactin receptor expression by rat NK cells.

Chambers WH, Amoscato AA, Smith MS, Kenniston TW, Herberman RB, Appasamy PM.

Nat Immun. 1995;14(3):145-56.

PMID:
8832898
49.

Divergent signal transduction pathways and effects on natural killer cell functions induced by interaction of Fc receptors with physiologic ligands or antireceptor antibodies.

Sulica A, Chambers WH, Manciulea M, Metes D, Corey S, Rabinowich H, Whiteside TL, Herberman RB.

Nat Immun. 1995;14(3):123-33. Review.

PMID:
8832896
50.

Characterization and comparison of the lytic function of NKR-P1+ and NKR-P1-rat natural killer cell clones established from NKR-P1bright/TCR alpha beta-cell lines.

Brissette-Storkus C, Appasamy PM, Hayes LA, Kaufman CL, Ildstad ST, Chambers WH.

Nat Immun. 1995;14(2):98-113.

PMID:
8601077

Supplemental Content

Loading ...
Support Center